Cancer Stem Cell Patient Stratification & Response Prediction Service
Creative Biolabs delivers a sophisticated diagnostic and analytical framework designed to identify the specific patient populations most likely to derive clinical benefit from your candidate compounds. By targeting the "roots" of cancer, the cancer stem cells (CSCs), we provide the biological clarity required to move beyond the limitations of bulk tumor analysis. Our service delivers actionable data on drug-specific sensitivity and resistance mechanisms, ensuring that your clinical resources are allocated to the most promising patient cohorts.
Introduction to CSC Patient Stratification
Creative Biolabs employs a consensus stemness ranking (CSR) approach to resolve the limitations of traditional bulk tumor analysis. By integrating scRNA-seq and m6A mapping, we move beyond superficial markers to define a tumor's true regenerative potential. These high-resolution signatures distinguish between "immune-cold" and "hot" microenvironments, providing the biological resolution necessary to predict therapeutic failure or metastatic spread. Our service establishes a definitive framework for personalized oncology, identifying resilient quiescent cells to significantly reduce the risk of late-stage clinical trial failure.
Comprehensive Stratification Solutions
To ensure the highest predictive accuracy, Creative Biolabs offers an integrated suite of advanced analytical modules. We provide more than just data; we provide a biological context for your drug's performance across diverse patient populations.
Advanced Epitranscriptomic Profiling
We offer specialized m6A-seq and MeRIP-seq services to identify RNA methylation patterns (such as the FTO/METTL3 axis) that regulate CSC self-renewal. This allows for stratification based on the "epigenetic state" of the tumor.
Multiplexed Single-Cell Proteomics
Our platform identifies co-expression patterns of over 40 protein markers simultaneously. By quantifying markers like CD44, CD133, and ALDH1 at the single-cell level, we define the exact phenotypic maturity of the CSC niche.
Metabolic Plasticity Assessment
We analyze the metabolic flux of patient-derived samples to determine if your compound effectively targets CSCs that have "rewired" their metabolism to survive under glucose-deprived or hypoxic conditions.
AI-Powered Signature Ranking
Using our CSR algorithm, we offer a unified "stemness score" that integrates ESC and iPS signatures, providing a more stable and reproducible biomarker.
Circulating CSC Liquid Biopsy
For non-invasive monitoring, we offer the detection and molecular profiling of disseminated CSCs from peripheral blood, enabling real-time response prediction throughout the trial.
Empower Your Project with Multi-Omic Clarity — Contact Our Technical Team for a Detailed Service Brochure
Workflow
The Creative Biolabs workflow is a comprehensive, multi-stage process that integrates computational prediction with functional biological evidence to provide a holistic view of patient response.
Publication
This review comprehensively examines ex vivo tumor culture systems for functional drug testing and therapy response prediction in personalized oncology. It compares established and emerging models, including 2D monolayers, 3D organoids, patient-derived xenografts, and organotypic tissue slices, evaluating their ability to preserve tumor heterogeneity and microenvironment for accurate treatment stratification.
Fig.1 The utility of ex vivo models in research and drug discovery. 1
Why Choose Us?
Creative Biolabs harmonizes single-cell resolution with AI-driven analytics to capture the dynamic plasticity of the CSC niche. Our platform moves beyond static biomarkers, utilizing proprietary algorithms refined by published clinical data to ensure superior values and predictive accuracy. We deliver regulatory-ready reports designed for submissions and trials, transforming biological complexity into successful therapeutic outcomes across solid and hematological malignancies. Choosing Creative Biolabs means partnering with an innovator dedicated to transforming the biological complexity of cancer into successful therapeutic outcomes through unparalleled expertise in epitranscriptomics, proteomics, and functional ex vivo modeling.
Partner with the Leaders in CSC Research — Experience the Creative Biolabs Advantage Today
FAQs
How does your service address the high plasticity of CSCs?
We utilize a consensus-based approach (CSR) that looks at shared biological traits across ESC and iPS models rather than single surface markers, ensuring the stratification remains accurate despite phenotypic shifts.
Is this service compatible with immunotherapy development?
Yes. Our SCPM model assesses immune cell infiltration and HLA expression patterns, ideal for predicting response to immune checkpoint inhibitors.
What makes your AI models more reliable than standard bioinformatics?
We use ensemble machine learning trained on massive, curated clinical datasets, providing predictive power that exceeds standard univariate analysis.
Customer Review
-
Precision Stratification Results
Using Creative Biolabs' CSC stratification in our research has significantly facilitated the identification of rare persister cells. The multiplexed proteomics provided the level of detail necessary for our stakeholders. - Dr. Alan Sc*** -
Exceptional Analytical Depth
Creative Biolabs provided the most comprehensive metabolic profiling we have seen in the industry, helping us understand CAR-T exclusion zones. - Prof. Mi***
Related Services
Cancer Stem Cell Off-Target Risk Evaluation Service
Creative Biolabs validates lineage-specific safety margins, distinguishing quiescent CSCs from healthy regenerative niches. We optimize the therapeutic index to eliminate recurrence seeds while preventing systemic toxicity.
Learn More →Antibody Discovery Services
Creative Biolabs provides end-to-end antibody discovery, leveraging phage display and hybridoma platforms. We accelerate the development of humanized, bispecific, and conjugated antibodies with optimized efficacy and pharmacology.
Learn More →How to Contact Creative Biolabs
Creative Biolabs is your dedicated partner in overcoming the complexities of tumor heterogeneity. By focusing on the regenerative engine of the tumor, the CSC, we provide the precision and biological depth required for modern oncology.
Don't let CSC-mediated resistance derail your clinical development. Partner with Creative Biolabs to transform the complexity of cancer stem cells into a clear roadmap for patient success.
Reference
- Meijer, Titia G., et al. "Ex vivo tumor culture systems for functional drug testing and therapy response prediction." Future science OA 3.2 (2017): FSO190. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.4155/fsoa-2017-0003
Download our brochure